Merck's Cancer Drug Zolinza Approved
The FDA has approved Zolinza, Merck's first new cancer drug in about 20 years. The drug has been approved to treat cutaneous T-cell lymphoma, a rare form of non-Hodgkin's lymphoma.
While the market as a treatment for the cancer, also called CTCL, is limited, Merck is studying the drug as a tumor-fighting treatment in many other cancers, including of the breast and lung. Additional approvals from the FDA could vastly expand the market for the drug, also known as vorinostat.
Filed under Zolinza